Calcium channel antagonists reduce restenosis after percutaneous transluminal angioplasty of an arteriovenous fistula in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 3, 2008, Pages 232-236

  Doi, Shigehiro ^a   Masaki, Takao ^a   Shigemoto, Kenichiro ^b   Harada, Satoru ^b   Yorioka, Noriaki ^a,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Harada Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Arteriovenous fistula; Calcium channel antagonist; Hemodialysis; Percutaneous transluminal angioplasty; Restenosis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CORRELATION COEFFICIENT; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ARTERIOVENOUS SHUNT, SURGICAL; CALCIUM CHANNEL BLOCKERS; CONSTRICTION, PATHOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RECEPTORS, ANGIOTENSIN; REGRESSION ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR PATENCY;

EID: 44349111063     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00579.x     Document Type: Article

References (21)

1. Turmel-Rodrigues L. Dilatation and declotting of arteriovenous accesses. Ther Apher Dial 2003 7 : 244 51.
2. Nakai S, Shinzato T, Nagura Y et al. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004 8 : 3 32.
3. Quinn SF, Schuman ES, Demlow TA et al. Percutaneous transluminal angioplasty versus endovascular stent placement in the treatment of venous stenoses in patients undergoing hemodialysis: intermediate results. J Vasc Interv Radiol 1995 6 : 851 5.
4. Ohira S, Naito H, Amano I et al. 2005 Japanese Society for Dialysis Therapy guidelines for vascular access construction and repair for chronic hemodialysis. Ther Apher Dial 2006 10 : 449 62.
5. Amano I, Ohira S, Goto Y et al. In preparation for a treatment guideline for suitable vascular access repair in Japan. Ther Apher Dial 2006 10 : 364 71.
6. Sreedhara R, Himmelfarb J, Lazarus JM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994 45 : 1477 83.
7. Schmitz PG, Mccloud LK, Reikes ST et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002 13 : 184 90.
8. Gradzki R, Dhingra RK, Port FK et al. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001 38 : 1240 4.
9. Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog Cardiovasc Dis 1997 39 : 361 98.
10. Yokoi H, Daida H, Kuwabara Y et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997 30 : 855 62.
11. Tamai H, Katoh O, Suzuki S et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast Restenosis following Angioplasty Trial (TREAT). Am Heart J 1999 138 : 968 75.
12. Hillegass WB, Ohman EM, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994 73 : 835 9.
13. Dens J, Desmet W, Piessens J. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. Am Heart J 2003 145 : 404 8.
14. Dens JA, Desmet WJ, Coussement P et al. Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. Am J Cardiol 2001 87 : 28 33.
15. Jorgensen B, Simonsen S, Endresen K et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000 35 : 592 9.
16. Mancini GB, Miller ME, Evans GW, Byington R, Furberg CD, Pitt B, PREVENT Study Group. Prospective randomized evaluation of the vascular effects of norvasc. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of Norvasc trial (PREVENT). Am J Cardiol 2002 15 : 1414 16.
17. Levy-Toledano S, Maclouf J, Caen JP. Biochemical messengers of platelet activation. Nouv Rev Fr Hematol 1985 27 : 203 4.
18. Cohn JN. Calcium-entry blockers in coronary artery disease: introduction. Circulation 1982 65 : I1 2.
19. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999 31 : 275 81.
20. Parmley WW, Blumlein S, Sievers R. Modification of experimental atherosclerosis by calcium-channel blockers. Am J Cardiol 1985 55 : 165B 171B.
21. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997 30 : 569 75.